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Summary
Objective: To investigate the in vitro effects of dehydroepiandrosterone (DHEA) on neonatal rat chondrocytes.
Design: Chondrocytes isolated from neonatal rat cartilage were cultured in three-dimensionally agarose beads and were treated with DHEA.
Methods: Primary culture of chondrocytes was harvested from newbornWistar rats. The DHEA effects on chondrocyte activities were evaluated
by analyzing chondrocyte proliferation,matrix protein synthesis, geneexpressions of collagen,matrixmetalloproteinase-1, -3 and -13 (MMP-1, -3
and -13), and cyclooxygenase-2 (COX-II), and protein synthesis of interleukin-6 (IL-6), prostaglandin E2 (PGE2) and tissue inhibitor of metal-
loproteinase-1 (TIMP-1).
Results: The DHEA treatment did affect chondrocyte proliferation and glycosaminoglycan (GAG) synthesis. DHEA suppressed the expression
of MMP-1, -3 and -13 genes and PGE2 protein synthesis enhanced by lipopolysaccharide (LPS) while the COX-II and inducible nitric oxide
synthase (iNOS) gene expressions were down-regulated by DHEA.
Conclusions: Our study demonstrates that DHEA has an ability to modulate the imbalance between MMPs and PGE2 in the neonatal chon-
drocytes which suggest that it has a potential protective role against articular cartilage damage.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage
Repair
SocietyIntroduction
Osteoarthritis (OA) is a degenerative joint disease charac-
terized by loss of articular cartilage, subchondral bone re-
modeling, joint space narrowing, and bone spur formation.
There are several treatment modalities, including adminis-
tration of non-steroid anti-inﬂammatory drugs (NSAIDs)1
or steroids2, physical therapy, and surgery as a last resort.
Although intraarticular corticosteroid injection has been rec-
ommended for the relief of pain and swelling, adverse ef-
fects (such as possible infection) and concerns about the
possible development of progressive cartilage damage
have limited its wider usage3,4. Meanwhile, intraarticular in-
jection of hyaluronan is now frequently performed for the
palliation of joint pain and has been reported to have
some positive effects on the maintenance of cartilage matrix
integrity during the development of OA5. However, the
mechanism of action of hyaluronan remains unclear.
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hormone classiﬁed as an adrenal androgen. DHEA is syn-
thesized from pregnenolone (derived from cholesterol)
and is rapidly sulfated to its ester form, DHEA-sulfate found
in circulating plasma6. Numerous studies of DHEA in vari-
ous disease conditions, such as atherosclerosis7, cancer8,
diabetes9, obesity10, aging11, and inﬂammatory arthritis
(such as rheumatoid arthritis)12, have been conducted. In
rheumatoid arthritis patients, the serum level of DHEA has
been found to be lower than in healthy controls13, while
the cause remains unknown. In addition, the exogenous ad-
ministration of DHEA was found to offer protection against
the development of collagen-induced arthritis in an animal
model14.
Although rheumatoid arthritis shares some aspects with
OA, there is little information about the effects of DHEA
on OA. Recently, the effect of DHEA on collagenase and
gelatinase productions has been reported15. Later, DHEA
has been demonstrated to have an ability to modulate the
transcriptional imbalance between matrix metalloprotei-
nases (MMPs) and tissue inhibitor of metalloproteinases-1
(TIMP-1) of human osteoarthritic knee chondrocytes cul-
tured in three-dimensionally alginate beads, which suggests
that DHEA has a protective role against articular cartilage
loss16. The aim of the present study was to investigate
whether DHEA has a protective role against articular8
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used to simulate pyogenic arthritis17 while S-nitroso-N-ace-
tyl-L-penicillamine (SNAP) treatment was used to simulate
degenerative arthritis18. The in vitro effects of DHEA on
chondrocyte metabolism were evaluated by the analysis
of the DHEA effects on the changes of the matrix protein
and various inﬂammatory mediators.
Materials and methods
ISOLATION OF NEONATAL CHONDROCYTES
Newborn Wistar rats (3 days old) were obtained from the
laboratory center of the Medical College, National Taiwan
University. Fibrous tissue was dissected from the articular
cartilage under sterile conditions. Cartilage was washed
with calcium- and magnesium-free phosphate buffered sa-
line (DPBS, Sigma Co., St. Louis, MO, USA), pH 7.4 contain-
ing 0.1% (wt/vol) ethylenediaminetetra-acetic acid (EDTA),
immersed twice for 20 min, and then ﬁnely minced. Chondro-
cytes were released from articular cartilage after being di-
gested with 0.2% pronase (Sigma, St. Louis, MO, USA) for
1 h, followed by digestion in PBS containing 0.25% (wt/vol)
trypsin and 0.05% (wt/vol) EDTA (Gibco BRL, Rockville,
MD, USA) at 37(C for 1 h. After the three washes with
PBS, the tissues were digested for 3 h with PBS containing
0.1% (wt/vol) collagenase (Sigma Co., St. Louis, MO, USA)
in high-glucose Dulbecco’s modiﬁed Eagle medium (DMEM;
Life Technologies, Rockville, MD, USA) containing antibioti-
ceantimycotic solution (100 U/mL penicillin, 100 mg/mL
streptomycin, and 0.25 mg/mL amphotericin B; Life Technol-
ogies) at 37(C. After removing undigested cartilage using
a 70 mm nylon sieve, the chondrocytes were collected bycentrifugation, washed twice, re-suspended in DMEM sup-
plemented with 10% fetal bovine serum (FBS; Life Technol-
ogies), 25 mg/mL L-ascorbic acid (Sigma) and antibiotics,
and ﬁnally plated in 100-mm tissue culture dish in DMEM
(Gibco) supplemented with 10% (vol/vol) fetal calf serum
(Gibco), penicillin (100 U/mL) and streptomycin (100 mg/
mL) for expansion at 37(C in a humidiﬁed atmosphere of
5% CO2 for 7 days. Surgical procedures and experimental
protocols were approved and under supervision by the Med-
ical College’s Animal Research Committee of the National
Taiwan University and have been carried out in accordance
with the Declaration of Helsinki.
CULTURE OF CHONDROCYTES IN AGAROSE GEL
After 7 days in monolayer culture, chondrocytes were
washed in PBS (twice) and harvested with 0.25% trypsi-
neEDTA solution for 1 min at 37(C in a humidiﬁed atmo-
sphere of 5% CO2. The total cell yield was calculated
using a hemocytometer and the trypan blue exclusion as-
says. The chondrocyte suspension was added to an equal
volume of molten 4% (wt/vol) agarose type VII (Sigma Co.,
St. Louis, MO, USA) in PBS to yield a ﬁnal cell concentra-
tion of 1 107 cells/mL in 2% (wt/vol) agarose for each
sub-population. Each chondrocyte/agarose suspension
was poured into sterile 96-well pre-designed molds
(Fig. 1) and allowed to gel at 40(C for 20 min.
The specimens were placed into separate wells of 6-well
tissue culture plates and immersed in 6 mL of DMEM
(Gibco) supplemented with 10% (vol/vol) fetal calf serum
(Gibco), penicillin (100 U/mL) and streptomycin (100 mg/
mL) and predetermined concentrations of DHEA. At the
end of the experimental period, the culture medium wasFig. 1. Pre-designed 96-well molds for chondrocyte/agarose suspension gelling system.
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specimens were removed from culture and incubated at
70(C in 0.5 mL PBS supplemented with 10 mM EDTA
and 10 mM L-cysteine hydrochloride until molten (4 h).
The suspension was cooled to 40(C and 5 ml/mL papain
(560 U/mL) suspension and 10 ml/mL agarose (1000 U/mL)
were added to each sample before being incubated for
24 h at 40(C19.
EFFECT OF DHEA ON LPS, SNAP-INDUCED ARTHRITIS
In this study, we used 105 g/mL LPS (Escherichia coli
0111:B4; Sigma Chemical, St. Louis, MO, USA) to simulate
pyogenic arthritis17 and 105 M SNAP (Sigma Chemical, St.
Louis, MO, USA) to simulate degenerative arthritis18. In
a series of experiments on cell proliferation and glycosami-
noglycan (GAG) synthesis, chondrocytes in monolayer cul-
ture for proliferation assay or chondrocytes in agarose gel
for GAG assay and gene expression were incubated in
growth medium with 105, 106, 107, 108 M of DHEA
(Sigma) for 7 days.
COLORIMETRIC MTT (TETRAZOLIUM) ASSAY
FOR CELL VIABILITY
For the assay, cells were incubated in 96-well plates in
the presence of various concentrations of DHEA. For 3-
(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) test of chondrocytes, 6250 cells/well were added to
96-well plates, the cells were cultured for 2 days without
treatment to facilitate the attachment of cells and then var-
ious concentrations of DHEA were added. After various
time intervals (1 day, 2 days or 4 days) the supernatant
was removed, 100 ml of MTT solution (Sigma catalog no.
M2128, Sigma Co., St. Louis, MO, USA; 1 mg/mL) was
added to each well. The plate was incubated at 37(C for
4 h to allow the formation of formazan crystals. The dark
blue crystals were dissolved by acid-isopropanol, then the
plate was read on Microelisa reader (Emax Science
Corp., Sunnyvale, CA, USA).
GAG AMOUNT ASSAY
At the 6th day, the beads were dissolved as described
previously and centrifuged at 300 g for 10 min at 4(C, ob-
taining a pellet containing cells with their cell-associated
matrix (CM). For GAG amount assay, the pellets were di-
gested for 12 h at 55(C in papain buffer (200 mg/mL papain
in 50 mM EDTA, 5 mM L-cysteine, pH 3.0). GAG amount
was quantiﬁed using dimethylmethylene blue (DMB) as-
say20. The metachromatic reaction of GAG with DMB was
monitored using a spectrophotometer, and the ratio
A540:A595 was used to determine the amount of GAG pres-
ent, using chondroitin sulfate C (Sigma) as a standard.
ANALYSIS OF HYDROXYPROLINE (OHP) CONTENT
OHP content was measured using the Ehrlich’s reaction
assay as previously described21. Aliquots (50 ml) of scaffold
digests, after proper dilutions, were hydrolyzed in 6 N HCl at
110(C for 18 h and then lyophilized. The samples were
then reconstituted in 200 ml of the assay buffer [5 g/L citric
acid (monohydrate), 12 g/L sodium acetate (trihydrate),
3.4 g/L sodium hydroxide, and 1.2 mL/L glacial acetic acid
in distilled water, pH 6.0]. The reconstituted sample solu-
tions were subsequently ﬁltered through activated charcoal.Added to 50 ml of each ﬁltered sample in a 96-well plate was
50 ml of 62 mM chloramine-T (Sigma). The mixture was in-
cubated at room temperature for 15 min to allow oxidation
reaction. Oxidized samples were then mixed with 50 ml of
0.94 M dimethylaminobenzaldehyde (p-DMBA) colorimetric
solution and incubated at 37(C for 30 min. The optical den-
sities of the assayed samples were measured using a plate
reader at 540 nm, and the OHP content of the samples was
computed relative to a standard curve of trans-4-hydroxy-L-
proline (0e300 mg/mL).
BIOCHEMICAL ANALYSIS OF NITRIC OXIDE (NO) METABOLISM,
PROSTAGLANDIN E2 (PGE2) AND INTERLEUKIN-6 (IL-6)
PRODUCTION
Quantification of NO release
The concentration of nitrite, the stable end product of NO
oxidation, was used as an indicator of NO synthesis. Nitrite
concentration in the culture medium was measured spectro-
photometrically using the Griess reaction with sodium nitrite
as the standard22. Brieﬂy, an aliquot (100 ml) of culture me-
dium was incubated with 50 ml of 0.1% sulfanilamide in 5%
phosphoric acid and 50 ml of 0.1% N-1-naphthyl-ethylenedi-
amine dihydrochloride (Sigma). After a 10 min incubation
period at room temperature, absorbance was measured at
550 nm.
Analysis of PGE2 in culture medium
The production of PGE2 in culture medium was also an-
alyzed by enzyme-linked immunosorbent assay (ELISA)
methods. Brieﬂy, 50 ml of standard PGE2 (R & D System,
Inc., USA) or sample was added per well. The tested sam-
ples were incubated on the benchtop for 18 h at room tem-
perature. Then 200 ml of Ellman’s Reagent was added to
each well and incubated for 1.5 h at room temperature.
The reaction was stopped and read by a Microelisa reader
(Emax Science Corp., Sunnyvale, CA, USA) at 405 nm.
Analysis of IL-6 and TIMP-1 in culture medium
The productions of IL-6 and TIMP-1 in culture medium
were analyzed by ELISAmethods. Brieﬂy, 200 ml of standard
or sample was added per well. The tested samples were
incubated for 3 h at room temperature, then 200 ml of IL-6
(Ray Biotech, Inc. Norcross, GA 30092, USA) conjugate
was added and incubated for 1.0 h at room temperature.
Two hundred microliters of substrate solution was added to
eachwell. The reactionwas stopped and readby aMicroelisa
reader (Emax Science Corp., Sunnyvale, CA, USA) at
450 nm after 20 min of incubation. Similar procedure was
performed for the analysis of TIMP-1 (Bio-Rad Laboratories,
Inc., USA).
STATISTICAL ANALYSIS
Two-way ANOVA with post hoc Bonferroni-corrected t
tests was used to examine inter- and intra-group differences
for cultured and absolute data. Unpaired Student’s t tests
were used to examine normalized data. In all cases, a level
of 5% was considered as statistically signiﬁcant.
RNA ISOLATION AND CDNA SYNTHESIS
After various time intervals the supernatant was removed,
total RNA was isolated from cell cultures using the
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with the aid of ABI PRISM 6100 Nucleic Acid PrepStation
(ABI, Foster City, CA, USA) following the manufacturer’s
protocol. Reverse transcription (RT), polymerase chain re-
action (PCR), and real-time PCR reagents were supplied
by Applied Biosystems (Foster City, CA, USA). For cDNA
synthesis, the following reagents were added to a ﬁnal vol-
ume of 20 ml: 4 ml of 5 reaction buffer, 2 ml of 25 mM
MgCl2, 2 ml dithiothreitol, 0.5 ml RNase inhibitor, 1 ml random
hexamer, 1 ml oligo(dT) primer, and 2 ml of 10 mM dNTP
mixture. All tubes were heated to 65(C for 5 min and then
allowed to cool at room temperature for 10 min. All RT tubes
received 1 ml of diethylpyrocarbonate (DEPC)-treated water
and all other (positive) tubes received 1 ml (50 U) of Multi-
scribe reverse transcriptase. All reactions were incubated
for 10 min at room temperature and then transferred to
a 37(C heat block for 60 min. Reactions were halted by
heating to 95(C for 5 min and cooling on ice.
REAL-TIME QUANTITATIVE RT-PCR (QRT-PCR)
Real-time QRT-PCR was performed using an ABI Prism
7000 Sequence Detector (Applied Biosystems, Foster
City, CA, USA). Primers were designed and synthesized
by Applied Biosystems, USA (Table I). Quantitative PCR
conditions were (stage 1) 95(C for 10 min and (stage 2)
40 cycles at 95(C for 15 s, 60(C for 30 s, and 72(C for
2 min. In the ﬁnal cycle (stage 3) products were heated
slowly to 95(C while ﬂuorescence measurements were
used to generate a dissociation curve utilizing the software
program v1.Ob1 provided by Applied Biosystems. From
such melting curves, the degree of product purity was as-
sessed23. Amplicons were also electrophoresed on a 4%
agarose gel to verify a single band at the appropriate molec-
ular weight.
Quadruplicate threshold cycle (CT) values were generated
for each sample and averaged, and standard deviations (one
SD of the means) were calculated. The threshold cycle, CT,
is deﬁned as the PCR cycle at which an increase in amplicon
ﬂuorescence is detected over a set baseline value. The ap-
proach taken in this study utilized the comparative CT meth-
od for relative quantitation of gene levels of expression as
outlined in User Bulletin No. 2 from Applied Biosystems
(User Bulletin #2: ABI PRISM 7000 Sequence Detection
System, PE Applied Biosystems, Foster City, CA, 1997).
STATISTICAL ANALYSIS
All experiments were performed in triplicate. Results
were expressed as means standard deviation of three
experiments. Statistical comparisons were made using
KruskaleWallis test to examine differences between individ-
ual data points. Statistical signiﬁcance was set at P< 0.05.Results
EFFECTS OF DHEA ON CELL PROLIFERATION
AND SYNTHESIS OF GAG
The effect of DHEA on cell proliferation was examined at
DHEA concentrations of 105, 106, 107, 108 M after 1,
2, and 4 days of culture [Fig. 2(A)]. Chondrocytes at every
concentration proliferated actively but signiﬁcant differences
were observed between cells treated with DHEA at the 1st
day of culture (n¼ 9; P< 0.05). This result demonstrated
that DHEA treatment did affect chondrocyte proliferation
at these concentrations. We chose 106 M DHEA for further
evaluation because there was a universal beneﬁcial effect
on the chondrocytes at this concentration.
The effect of DHEA on GAG synthesis was examined by
DMB assay at various DHEA concentrations after 6 days of
culture [Fig. 2(B)]. Although, the total amount of GAG syn-
thesis increased with the addition of DHEA at all concentra-
tions, no statistical signiﬁcance was found [P> 0.05]. These
results suggested that DHEA did not impair the GAG pro-
duction by chondrocytes.
EFFECT OF DHEA ON LPS-TREATED CHONDROCYTES
Cell proliferation and synthesis of GAG and OHP
In a series of experiments on cell proliferation, chondro-
cytes in monolayer culture were incubated in growth medi-
um with 105 g/mL LPS up to 48 h. In the presence of
105 g/mL LPS, the viability of chondrocytes was signiﬁ-
cantly decreased at 48 h of culture period [Fig. 3(A)].
When 105 g/mL of LPS was added to the chondrocyte
culture, the syntheses of GAG and collagen were signiﬁ-
cantly inhibited [P< 0.05, Fig. 3(B)] while the DHEA can
partially reverse this effect; this beneﬁcial effect attained
its maximal effect at the concentration of 106 M DHEA
[Fig. 3(B)]. The synthesis of OHP was also signiﬁcantly
higher than that of negative control [Fig. 3(B)]; this fact im-
plied that the impairment of GAG production by chondro-
cytes can be completely reversed by adding DHEA.
Secretion of TIMP-1, IL-6 and PGE2
The effects of DHEA on the secretion of TIMP-1, IL-6 and
PGE2 were investigated in the presence of LPS. For the IL-6
synthesis, the treatment of LPS can signiﬁcantly increase
the IL-6 secretion by chondrocytes (P< 0.0005), but the ad-
dition of DHEA did not affect the amount of IL-6 secretion
after LPS treatment of the chondrocytes (Fig. 4). For the
TIMP-1, the treatment of LPS can signiﬁcantly decrease
the TIMP-1 secretion at the 4th day of culture while this ef-
fect was partially reversed at the 4th and 6th days of culture
by 106 M DHEA when compared with that of positive con-
trol [Fig. 5(A)]. The synthesis of PGE2 was signiﬁcantlyTable I
Polymerase chain reaction primer sequences
Gene GeneBank accession number Sequence PCR product (bp)
Sense Anti-sense
b-Actin X03672 5#-CCATCATGAAGTGTGACGTTGA-3# 5#-CTTCTGCATCCTGTCAGCAATG-3# 103
COX-II NM_011198 5#-CTGACCCCCAAGGCTCCA-3# 5#-CCAGGTCCTCGCTTATGA-3# 94
iNOS NM_011198 5#-CTGACCCCCAAGGCTCCA-3# 5#-CCAGGTCCTCGCTTATGA-3# 81
MMP-1 MMU54984 5#-GCCCACGGACAAGATCGA-3# 5#-ACTTATTGCCCCGGAAGA-3# 103
MMP-3 NM_010809 5#-CCTTTTGATGGGCCTGGAA-3# 5#-ATCGTCAAAGTGAGCATC-3# 94
MMP-13 NM_008607 5#-CTTGTGTTTGCAGAGCACTA-3# 5#-ACTGTGGAGGTCACTGTAGA-3# 81
242 J.-S. Sun et al.: The effects of DHEA on chondrocyte metabolismFig. 2. The effect of DHEA on chondrocyte proliferation and GAG synthesis. (A) Six thousand chondrocytes were initially plated in each well of
a 96-well plate and treated with DHEA at 0, 0.1, 1, 10 mM. On days 1, 2 and 4, the number of viable cells was measured by MTT assay. Chon-
drocytes actively proliferated during culture, and signiﬁcant differences in viable cell numbers were observed at 0.1 and 1 mM concentrations
(n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005). (B) The effect of DHEA on GAG synthesis was examined by DMB assay at
various DHEA concentrations after 6 days of culture. Although, the total amount of GAG synthesis increased with the addition of DHEA at all
concentrations, no statistical signiﬁcance was found (P> 0.05).increased by LPS treatment at 105 M (P< 0.05) while the
treatment of DHEA can signiﬁcantly inhibit the effect of LPS
on the chondrocytes in the ﬁrst 2 days of culture [Fig. 5(B)].
Gene expressions of cyclooxygenase-2 (COX-II),
MMP-1, -3, -13 and inducible nitric
oxide synthase (iNOS)
Quadruplicate PCRs produced nearly identical results. In
this study, the PCR products of b-actin were detected in all
RNA preparations, which conﬁrmed the uniformity of the
RNA preparations. ThemRNA expression of COX-II was sig-
niﬁcantly increased by LPS treatment at 105 g/mL
(P< 0.05) while with the treatment of 106 M DHEA, the
COX-II gene expression was 0.39 times than that of the pos-
itive control (Table II). For theMMP-1 gene expression, there
was no signiﬁcant effect by the treatment of LPS when com-
pared with that of negative control; but the adding of DHEA
can signiﬁcantly decrease the expression of MMP-1 gene
when compared to that of positive control with any other treat-
ment (Table II). For the MMP-3 and -13 gene expressions,
the addition of 106 M DHEA into LPS-treated chondrocytes
can signiﬁcantly down-regulate their gene expression
(Table II). For the iNOS gene expression, although thegene expression was up-regulated in the presence of LPS
and also can be reversed by DHEA; all these effects did
not attain a statistically signiﬁcant level (P¼ 0.056; Table II).
EFFECT OF DHEA ON SNAP- AND H2O2-TREATED
CHONDROCYTES
Effect of DHEA on H2O2-treated chondrocytes
In a series of experiments on cell proliferation, chondro-
cytes in monolayer culture were incubated in growth medium
with 0.015% H2O2 up to 48 h. In the presence of 0.015%
H2O2, the viability of chondrocytes was signiﬁcantly de-
creased during the 7 h culture period, but the deleterious
effect was partially compensated by the addition of 106 M
DHEA in the 7 h culture [Fig. 6(A)].
EFFECT OF DHEA ON SNAP-TREATED CHONDROCYTES
Synthesis of NO
The effect of DHEA on NO synthesis was examined by
Griess reaction at DHEA concentrations of 105, 106,
107, 108 M after 6 days of culture. Basically, the amount
243Osteoarthritis and Cartilage Vol. 14, No. 3Fig. 3. The effect of DHEA on LPS-stimulated chondrocytes. (A) In
a series of experiments on cell proliferation, chondrocytes in mono-
layer culture were incubated in growth medium with 105 g/mL LPS
up to 48 h. In the presence of 105 g/mL LPS, the viability of chon-
drocytes was signiﬁcantly decreased at the 48 h culture period
(n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005).
(B) When 105 g/mL LPS was added to the chondrocyte culture,
the syntheses of GAG and collagen were signiﬁcantly inhibited
(P< 0.05) while the DHEA can partially reverse this effect. This
beneﬁcial effect attained its maximal effect at the concentration of
106 M DHEA (n ¼ 9; a: P value< 0.05; b: P value< 0.005; c:
P value< 0.0005).of NO synthesis was quite stationary during the 6 days of
culture period while after the addition of DHEA, a statistically
signiﬁcant decrease in the amount of NO synthesis was
found [P< 0.0005; Fig. 6(B)]. These results suggested
that DHEA does inhibit the NO synthesis by chondrocytes.
Various NO donors, such as nitrosocysteine, nitrosoglu-
tathione, sodium nitroprusside (SNP), SNAP, 3-morpholo-
syndonimine (SIN-1) have been previously reported24.
When 105 M SNAP was added, the synthesis of NO was
signiﬁcantly enhanced (P< 0.05), while the DHEA can re-
verse this effect, this beneﬁcial effect attained its maximal
level at the concentration of 106 M DHEA for the SNAP
test [Fig. 7(A)].
Synthesis of GAG
When 105 M SNAP was added to the chondrocyte cul-
ture, the synthesis of GAG was signiﬁcantly inhibited
(P< 0.05) while the DHEA can reverse this effect, this ben-
eﬁcial effect attained its maximal effect at the concentration
of 106 M DHEA [Fig. 7(B)]. This fact implied that the im-
pairment of GAG production by chondrocytes can be re-
versed by adding DHEA.
Discussion
OA is a chronic destruction of cartilage and bone. The
pathogenesis of arthritis is still unknown. Mediators of the
endocrine system, such as DHEA, androgen, estrogen,
and glucocorticoids, are all known to inﬂuence the disease
process of immune-related arthritis such as in rheumatoid
arthritis25e27. Among these endocrine mediators, DHEA
and its sulfate form, DHEAS, are the most abundant pro-
hormones formed in vivo28 and can be found in blood and
synovial ﬂuid26. Physiologic variations of DHEA levels
have been observed in lifetime, especially an increase in
puberty, with a maximum in the third decade and a massive
decline until the eighth decade29. The physiologic functions
of DHEA are still unclear, but beneﬁcial effects have been
found on the immune function of both animals and humans.Fig. 4. The effects of DHEA on the secretion of IL-6 by LPS-stimulated chondrocytes. For the IL-6 synthesis, the treatment of LPS can sig-
niﬁcantly increase the IL-6 secretion by chondrocytes (P< 0.0005), but the addition of DHEA did not affect the amount of IL-6 secretion after
LPS treatment on the chondrocytes (n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005).
244 J.-S. Sun et al.: The effects of DHEA on chondrocyte metabolismThe purpose of this study was to demonstrate the in vitro ef-
fects of DHEA on chondrocytes. We used agarose beads
as a three-dimensional scaffold to culture chondrocytes,
as they have been demonstrated to be bio-compatible
with chondrocytes30.
A few reports have been concerned with the proliferatione
inhibitory effect of DHEA in other cell types and have sug-
gested that the inhibition might occur via a DHEA-speciﬁc
receptor that involves extracellular signal-regulated kinase 1
(ERK1) signaling pathways31, via increasing G0eG1 cell pop-
ulations and simultaneously decreasing the number of cells ad-
vancing to the S and G2eM cell cycle phases32, or via
inhibition of glucose-6-phosphate dehydrogenase (G6PD)33.
In this work, DHEA treatment was found to enhance the
Fig. 5. The effects of DHEA on the secretion of TIMP-1 and PGE2.
The effects of DHEA on the secretion of TIMP-1, IL-6 and PGE2
were investigated in the presence of LPS. (A) The treatment of
LPS can signiﬁcantly decrease the TIMP-1 secretion at the 4th
day of culture while this effect was partially reversed at the 4th
and 6th days of culture in the presence of 106 M DHEA when com-
pared with that of the positive control (n¼ 9; a: P value< 0.05; b: P
value< 0.005; c: P value< 0.0005). (B) The synthesis of PGE2
was signiﬁcant ly increased by LPS treatment at 105 M
(P< 0.05) while the treatment of DHEA can signiﬁcantly inhibit
the effect of LPS on the chondrocytes in the ﬁrst 2 days of culture.
Treatment of LPS on chondrocytes can enhance the synthesis of
PGE2 while the addition of DHEA into chondrocytes can reverse
the LPS on PGE2 of the chondrocytes (n¼ 9; a: P value< 0.05;
b: P value< 0.005; c: P value< 0.0005).proliferation or viability of neonatal rat chondrocytes. These di-
vergent results reﬂect the current understanding of the effects
of DHEA on cell proliferation, which demonstrably remains
unclear.
In the present study, we analyzed the effects of DHEA on
chondrocyte proliferation, GAG synthesis, the protein and/
or gene expressions of PGE2, catabolic enzymes such as
MMP-1, -3, -13 and inhibitor of MMPs, such as TIMP-1,
which are known to play important roles in the progression
of OA. We found that DHEA has an ability to modulate the
imbalance between MMPs and TIMP-1, which suggests
that DHEA has a protective role against articular cartilage
loss. In this study, we used 105 g/mL LPS to simulate pyo-
genic arthritis17,34 and 105 M SNAP to simulate degenera-
tive arthritis18,35.
The present study demonstrates that DHEA treatment
does affect newborn chondrocyte proliferation but not
GAG synthesis. We chose 106 M DHEA for further evalu-
ation because there was a universal beneﬁcial effect on the
chondrocytes at this concentration.
In this study, we culture chondrocytes in the presence of
E. coli LPS to simulate bacterial arthritis. In the presence of
105 g/mL LPS, the viability of chondrocytes was signiﬁ-
cantly decreased after the 48 h culture period (Fig. 3); the
synthesis of GAG was also signiﬁcantly inhibited
(P< 0.05) while the DHEA can reverse this effect (Fig. 3).
Normally, chondrocytes cultured as monolayer undergo
a gradual dedifferentiation, characterized by a change
from a spherical shape to a ﬁbroblastic appearance. This
occurs with changes in the types of collagen synthesized
from type II into type I36. However, these changes have
been reported to be reversed when dedifferentiated chon-
drocytes are transferred into alginate, i.e., type II collagen
gene expression is up-regulated and type I collagen gene
expression is down-regulated37. In the present study, iso-
lated chondrocytes were cultured in monolayer for 7 days,
which resulted in some dedifferentiation of chondrocytes.
After transferring the monolayer-cultured chondrocytes to
agarose beads, they began to gradually re-express the dif-
ferentiated phenotype. In this study, the inhibition of colla-
gen synthesis by LPS treatment can be reversed by
DHEA treatment and the enhancement on the synthesis
of OHP was even higher than that of the negative control
(Fig. 3). This fact implied that DHEA has a potential protec-
tive effect on both the GAG and collagen synthesis of chon-
drocytes under pyogenic arthritis. We can suggest that the
treatment of DHEA may accelerate the synthesis of type II
collagen even in the presence of LPS treatment. However,
this needs to be further validated.
There are several proteinases involved in the degradation
of cartilage, including several MMPs, aggrecanases, and
other proteinases38 while the TIMPs are speciﬁc inhibitors
that participate in controlling the local activities of MMPs
in tissue39. In this study, the effects of DHEA on the secre-
tion of TIMPs and MMPs were also investigated. The
results showed that the addition of 106 M DHEA into
LPS-treated chondrocytes can signiﬁcantly down-regulate
their gene expression (Table II). In this neonatal rat chon-
drocytes, the synthesis of PGE2 and the expression of
COX-II mRNA were signiﬁcantly increased by LPS treat-
ment while the treatment of DHEA can signiﬁcantly inhibit
the effect of LPS on the chondrocytes (Table II).
For the inﬂammatory mediators affect the pathogenesis
of arthritis, various MMPs, including MMP-1 and -3 are
known to be expressed in human40 or experimentally in-
duced OA41,42, though their expression patterns are contra-
dictory41. The activities of MMPs are regulated not only by
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The effects of DHEA on the chondrocyte gene expressions
Actin (ppm) Mean COX-II Mean MMP-1 Mean MMP-3 Mean MMP-13 Mean iNOS
Control Mean 13.9 c 15.9 124.4 a 16.2 b 782.4
105 M LPS SD 11.6 2.1 177.5 24.5 1238.7
Controlþ Mean 2286.9 13.1 1219,361.9 2327.9 2297.9
105 M LPSþ SD 537.5 2.6 689,268.2 1049.2 307.2
106 M DHEA Mean 892.9 a 2.1 b 378,883.6 a 325.4 b 3759.3
105 M LPSþ SD 603.6 1.1 159,155.2 137.5 1335. 2
Ratio Mean Mean Mean Mean Mean
Controlþ/Control 164.60 0.82 9804.10 144.09 2.94
106 M DHEA/Controlþ 0.39 0.16 0.31 0.14 1.64
106 M DHEA/Control 64.26 0.13 3046.36 20.14 4.81
Data expressed as ppm of b-actin. Control: absence of 105 M LPS; Controlþ: presence of 105 M LPS; 106 M DHEA: presence of
105 M LPS and 106 M DHEA. a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005.
Fig. 6. The effects of DHEA on the H2O2-treated chondrocytes and NO synthesis by chondrocytes. (A) In a series of experiments on cell pro-
liferation, chondrocytes in monolayer culture were incubated in growth medium with 0.015% H2O2 up to 48 h. In the presence of 0.015% H2O2,
the viability of chondrocytes was signiﬁcantly decreased during the 7 h culture period, but the deleterious effect was partially compensated by
the addition of 106 M DHEA after the 7 h culture (n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005). (B) Basically, the amount
of NO synthesis was quite stationary during the 6 days of culture period while after the addition of DHEA, a statistically signiﬁcant decrease in
the amount of NO synthesis was found (P< 0.0005). These results suggested that DHEA does inhibit the NO synthesis by chondrocytes
(n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005).
246 J.-S. Sun et al.: The effects of DHEA on chondrocyte metabolismFig. 7. Effect of DHEA on SNAP-treated chondrocytes. (A) The effect of DHEA on NO synthesis was examined by Griess reaction at DHEA
concentrations of 105, 106, 107, 108 M after 6 days of culture. When 105 M SNAP was added, the synthesis of NO was signiﬁcantly
enhanced (P< 0.05) while the DHEA can reverse this effect, this beneﬁcial effect attained its maximal level at the concentration of 106 M
DHEA for the SNAP test (n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005). (B) When 105 M SNAP was added to the chon-
drocyte culture, the synthesis of GAG was signiﬁcantly inhibited (P< 0.05) while the DHEA can reverse this effect, this beneﬁcial effect at-
tained its maximal effect at the concentration of 106 M DHEA (n¼ 9; a: P value< 0.05; b: P value< 0.005; c: P value< 0.0005).gene expression, but also by the extracellular activation of
proMMPs and by the inhibition of endogenous TIMPs’ inhib-
itors. In addition, cartilage destruction is believed to be
caused by an imbalance between activated MMPs and
TIMPs43. Previous studies had shown that the expression
of TIMPs has been thought to be relatively constant, regard-
less of the progression of experimentally induced OA44,
treatment with hyaluronic acid45 or with NSAIDs39 or IL-
1b46. However, dexamethasone and IL-1b treatments
were found to reduce the expression of TIMPs47. In this
study, we demonstrated that the gene expression of
MMP-1, -3 and -13 up-regulated by LPS treatment can be
signiﬁcantly suppressed by DHEA treatment, which sug-
gests that DHEA effects take place at the gene level in
the study. By contrast, DHEA has less effect on the gene
expression of TIMP-1, indicating that DHEA has an anti-
catabolic action, mainly via MMPs’ suppression, but less
via TIMP-1 induction in this in vitro model.
Prostaglandins may decrease chondrocyte proliferation,
modulate metalloprotease activity and inhibit aggrecan
synthesis48. Treatment of 105 M LPS can signiﬁcantly
increase the synthesis of PGE2 while the treatment ofDHEA can signiﬁcantly inhibit the effect of LPS on the chon-
drocytes in the ﬁrst 2 days of culture (Fig. 5). Similarly, the
mRNA expression of COX-II was signiﬁcantly up-regulated
by LPS treatment while with the treatment of 106 M DHEA
the COX-II gene expression was 0.39 times than that of the
positive control (Table II). NO has been shown to inhibit col-
lagen, proteoglycan synthesis, and induce chondrocytes
apoptosis24. Various NO donors, such as nitrosocysteine,
nitrosoglutathione, SNP, SNAP, SIN-1 have been re-
ported24. The presence of DHEA can inhibit the enhance-
ment of NO synthesis and the impairment of GAG
production by chondrocytes induced by SNAP. Taken to-
gether, DHEA has a protective effect during LPS-induced
chondrocyte injury.
The mechanisms of DHEA action in chondrocytes are not
clear. However, DHEA has been known to have anti-inﬂam-
matory effects, both in cells other than chondrocytes and/or
in vivo via the inhibition of pro-inﬂammatory cytokine secre-
tion, such as tumor necrosis factor (TNF)49, IL-150, and IL-
649. Moreover, the serum level of DHEA was found to be
negatively correlated with serum IL-6 in humans51. The
common mechanism of the anti-inﬂammatory action of
247Osteoarthritis and Cartilage Vol. 14, No. 3DHEA seems to concern the direct inhibition of nuclear fac-
tor kappa B (NF-kB) transfer to the nucleus52 via the activa-
tion of peroxisome proliferator activated receptor alpha
(PPARa), the inhibition of the binding of the nuclear factor
activator protein 1 (AP-1) to the DNA53, and peripheral con-
version to androgens and estrogens54. From this point of
view, it is interesting to note that the modulation of the
gene expressions of MMPs by IL-1 in chondrocytes is likely
to be mediated by serineethreonine kinases of the mitogen-
activated protein kinase (MAPK) family55, which comprises
ERK, the c-Jun N-terminal kinase (JNK), and p38. As the
endpoint of MAPK activation is the production of phosphor-
ylated active AP-1 transcription factor, which is composed
of c-Jun and c-Fos, the effect of DHEA on the suppression
of MMPs, presumably, and at least in part, is likely to be
exerted via the inhibition of the MAPK kinase pathway.
In addition, as IL-1 increases the activity of NF-kB, a tran-
scription factor that regulates numerous pro-inﬂammatory
genes, such as MMP-1 and -356,57, the inhibitory effects
of DHEA may blockade the IL-1-induced activity of
NF-kB (Fig. 8). Further studies are needed to elucidate
the precise role of DHEA in the production of chondrocyte
MMPs.
Conclusion
In our study on the effects of DHEA on neonatal rat chon-
drocytes, we demonstrate that DHEA does exert signiﬁcant
inﬂuence on cell proliferation or viability. For the inﬂamma-
tory mediators, the DHEA did inhibit PGE2 secretion and
COX-II gene expression induced by LPS. On the other
hand, DHEA does suppress the gene expressions and pro-
tein syntheses of MMP-1, -3 and -13 and with less effect on
TIMP-1. Furthermore, the DHEA has an ability to modulate
the imbalance between MMPs and TIMP-1, which suggests
that it has a protective role against articular cartilage loss.
However, the preliminary data obtained from this study
are only valid for the developing rat chondrocytes, further
studies on the human chondrocytes are mandatory to vali-
date the DHEA effect on the adult human OA.
Acknowledgements
This study was funded by National Science Council, ROC
and Taipei City Hospital.
COX-2
iNOS
NF-kB
Nucleus
Cytoplasma
LPS, TNF, IL-1, IL-6
MEKK-1 MAPKK
MAPK
NF-kB
NIK
IkK
IkB 
DHEA
Fig. 8.References
1. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F,
Jordan JM, et al. A randomized, double-blind, cross-
over clinical trial of diclofenac plus misoprostol versus
acetaminophen in patients with osteoarthritis of the hip
or knee. Arthritis Rheum 2001;44:1587e98.
2. Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C,
Noel E, et al. Effects of joint lavage and steroid injec-
tion in patients with osteoarthritis of the knee: results of
a multicenter, randomized, controlled trial. Arthritis
Rheum 1999;42:475e82.
3. American College of Rheumatology Subcommittee on
Osteoarthritis Guidelines. Recommendations for the
medical management of osteoarthritis of the hip
and knee: 2000 update. Arthritis Rheum 2000;43:
1905e15.
4. Pendleton A, Arden N, Dougados M, Doherty M,
Bannwarth B, Bijlsma JW, et al. EULAR recommenda-
tions for the management of knee osteoarthritis: report
of a task force of the Standing Committee for Interna-
tional Clinical Studies Including Therapeutic Trials
(ESCISIT). Ann Rheum Dis 2000;59:936e44.
5. Yoshioka M, Shimizu C, Harwood FL, Coutts RD,
Amiel DY. Long-term effects of hyaluronan on experi-
mental osteoarthritis in the rabbit knee. Osteoarthritis
Cartilage 1998;6:1e9.
6. Hornsby PJ. DHEA: a biologist’s perspective. J Am Ger-
iatr Soc 1997;45:1395e401.
7. Alexandersen P, Haarbo J, Christiansen C. The rela-
tionship of natural androgen to coronary heart disease
in males: a review. Atherosclerosis 1996;125:1e14.
8. Zumoff B, Levin J, Rosenfeld RS, Markham M,
Strain GW, Fukushima DK, et al. Abnormal 24-hour
mean plasma concentrations of dehydroepiandroster-
one and dehydroisoandrosterone sulfate in women
with primary operable breast cancer. Cancer Res
1981;41:3360e3.
9. ColemanDL, Schweitzer RW, Leiter EH. Effect of genetic
background on the therapeutic effects of dehydroepian-
drosterone (DHEA) in diabetes-obesitymutants in aged
normal mice. Diabetes 1984;33:26e32.
10. Barrett-Connor E, Ferrara A. Dehydroepiandrosterone,
dehydroepiandrosterone sulfate, obesity, waistehip
ratio, and non-insulin dependent diabetes in postmen-
opausal women: the Rancho Bernardo Study. J Clin
Endocrinol Metab 1996;81:59e64.
11. Watson RR, Hulls A, Araghi-Niknam M, Chung S. De-
hydroepiandrosterone (DHEA) supplementation to
prevent symptoms of aging. Drugs Aging 1996;9:
274e91.
12. Dessein PH, Joffe BI, Stanwix AE, Moomal Z. Hypose-
cretion of the adrenal androgen dehydroepiandroster-
one sulfate and its relation to clinical variables in
inﬂammatory arthritis. Arthritis Res 2001;3:183e8.
13. Cutolo M. Sex hormone adjuvant therapy in rheumatoid
arthritis. Rheum Dis Clin North Am 2000;26:881e95.
14. Williams PJ, Jones RH, Rademacher TW. Reduction in
the incidence and severity of collagen-induced arthritis
in DBA/1 mice, using exogenous dehydroepiandros-
terone. Arthritis Rheum 1997;40:907e11.
15. Lee KS, Oh KY, Kim BC. Effects of dehydroepiandros-
terone on collagen and collagenase gene expression
by skin ﬁbroblasts in culture. J Dermatol Sci 2000;
23:103e10.
16. Jo H, Park JS, Kim EM, Jung MY, Lee SH, Seong SC,
et al. The in vitro effects of dehydroepiandrosterone on
248 J.-S. Sun et al.: The effects of DHEA on chondrocyte metabolismhuman osteoarthritic chondrocytes. Osteoarthritis Car-
tilage 2003;11:585e94.
17. Hartert MM, Martin G, Devel P, Dupont GD,
Reginster JY, Henrotin Y. Reactive oxygen species
downregulate the expression of pro-inﬂammatory
genes by human chondrocytes. Inﬂamm Res 2003;
52:111e8.
18. Cao M, Larson AW, Niyibizi C, Kavalkovich K,
Georgescu HI, Rizzo CF, et al. Nitric oxide inhibits
the synthesis of type 2 collagen without altering
Col2A1 mRNA abundance: prolyl hydroxylase as
a possible target. Biochem J 1997;324:305e10.
19. Knight MM, Lee DA, Bader DL. The inﬂuence of elabo-
rated pericellular matrix on the deformation of isolated
articular chondrocytes cultured in agarose. Biochim
Biophys Acta 1998;1405:67e77.
20. Farndale RW, Buttle DJ, Barrett AJ. Improved quantita-
tion and discrimination of sulphated glycosaminogly-
cans by use of dimethylmethylene blue. Biochem
Biophys Acta 1986;883:173e7.
21. Neidert MR, Lee ES, Oegema TR, Tranquillo RT. En-
hanced ﬁbrin remodeling in vitro with TGF-beta1, insu-
lin and plasmin for improved tissue-equivalents.
Biomaterials 2002;23:3717e31.
22. Das P, Schurman DJ, Smith RL. Nitric oxide and G pro-
teins mediate the response of bovine articular chon-
drocytes to ﬂuid-induced shear. J Orthop Res 1997;
15:87e93.
23. Ririe KM, Rasmussen RP, Wittwer CT. Product differ-
entiation by analysis of DNA melting curves during
the polymerase chain reaction. Anal Biochem 1997;
245:154e60.
24. Clancy RM, Amin AR, Abramson SB. The role of nitric
oxide in inﬂammation and immunity. Arthritis Rheum
1998;41:1141e51.
25. Straub RH, Cutolo M. Involvement of the hypothalamic-
pituitary-adrenal/gonadal axis and the peripheral ner-
vous system in rheumatoid arthritis: viewpoint based
on a systemic pathogenetic role [review]. Arthritis
Rheum 2001;44:493e507.
26. Cutolo M, Seriolo B, Villaggio B, Pizzorni C,
Craviotto C, Sulli A. Androgens and estrogens modu-
late the immune and inﬂammatory responses in rheu-
matoid arthritis [review]. Ann N Y Acad Sci 2002;966:
131e42.
27. Dulos GJ, Bagchus WM. Androgens indirectly acceler-
ate thymocyte apoptosis. Int Immunopharmacol 2001;
1:321e8.
28. Bradlow HL, Murphy J, Byrne JJ. Immunological prop-
erties of dehydroepiandrosterone, its conjugates, and
metabolites. Ann N Y Acad Sci 1999;876:91e101.
29. Svec F, Porter JR. The actions of exogenous dehydroe-
piandrosterone in experimental animals and humans.
Proc Soc Exp Biol Med 1998;218:174e91.
30. Chowdhury TT, Bader DL, Lee DA. Dynamic compres-
sion inhibits the synthesis of nitric oxide and PGE2by
IL-1b stimulated chondrocytes cultured in agarose
constructs. BBRC 2001;285:1168e74.
31. Williams MR, Ling S, Dawood T, Hashimura K, Dai A,
Li H, et al. Dehydroepiandrosterone inhibits human
vascular smooth muscle cell proliferation independent
of ARs and ERs. J Clin Endocrinol Metab 2002;87:
176e81.
32. Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E,
Saboureau D, et al. Oxythiamine and dehydroepian-
drosterone induce a G1 phase cycle arrest in Ehrlichstumor cells through inhibition of the pentose cycle.
FEBS Lett 1999;456:113e8.
33. Di Monaco M, Pizzini A, Gatto V, Leonardi L, Gallo M,
Brignardello E, et al. Role of glucose-6-phosphate de-
hydrogenase inhibition in the antiproliferative effects of
dehydroepiandrosterone on human breast cancer
cells. Br J Cancer 1997;75:589e92.
34. Gilad E, Wong HR, Zingarelli B, Virag L, Oconnor M,
Salzman AL, et al. Melatonin inhibits expression of
the inducible isoform of nitric oxide synthase in murine
macrophages: role of inhibition of NFkB activation.
FASEB J 1998;12:685e93.
35. Shaffer JE, Han BJ, Chern WH, Lee FW. Lack of toler-
ance to a 24-hour infusion of s-nitroso n-acetylpenicill-
amine (SNAP) in conscious rabbits. J Pharmacol Exp
Ther 1990;260:286e93.
36. Mayne R, Vail MS, Mayne PM, Miller EJ. Changes in
type of collagen synthesized as clones of chick chon-
drocytes grow and eventually lose division capacity.
Proc Natl Acad Sci USA 1976;73:1674e8.
37. Binette F, McQuaid DP, Haudenschild DR, Yaeger PC,
McPherson JM, Tubo R. Expression of a stable articu-
lar cartilage phenotype without evidence of hypertro-
phy by adult human articular chondrocytes in vitro.
J Orthop Res 1998;16:207e16.
38. Visse R, Nagase H. Matrix metalloproteinases and tis-
sue inhibitors of metalloproteinases: structure, func-
tion, and biochemistry. Circ Res 2003;92:827e39.
39. Sadowski T, Steinmeyer J. Effects of non-steroidal anti-
inﬂammatory drugs and dexamethasone on the activ-
ity and expression of matrix metalloproteinase-1, ma-
trix metalloproteinase-3 and tissue inhibitor of
metalloproteinase-1 by bovine articular chondrocytes.
Osteoarthritis Cartilage 2001;9:407e15.
40. Chubinskaya S, Kuettner KE, Cole AA. Expression of
matrix metalloproteinases in normal and damaged ar-
ticular cartilage from human knee and ankle joints. Lab
Invest 1999;79:1669e999.
41. Bluteau G, Conrozier T, Mathieu P, Vignon E,
Herbage D, Mallein-Gerin F. Matrix metalloprotei-
nase-1, -3,-13 and aggrecanases-1 and -2 are differ-
entially expressed in experimental OA. Biochim
Biophys Acta 2001;1526:147e58.
42. Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L.
Anabolic and catabolic gene expression pattern analy-
sis in normal versus osteoarthritic cartilage using com-
plementary DNA-array technology. Arthritis Rheum
2001;44:2777e89.
43. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS,
Woessner JF Jr. Evidence for metalloproteinase and
metalloproteinase inhibitor imbalance in human osteo-
arthritic cartilage. J Clin Invest 1989;84:678e85.
44. Bluteau G, Gouttenoire J, Conrozier T, Mathieu P,
Vignon E, Richard M, et al. Differential gene expres-
sion analysis in a rabbit model of osteoarthritis in-
duced by anterior cruciate ligament (ACL) section.
Biorheology 2002;39:247e58.
45. Takahashi K, Goomer RS, Harwood F, Kubo T,
Hirasawa Y, Amiel D. The effects of hyaluronan on
matrix metalloproteinase-3 (MMP-3), interleukin-1beta
(IL-1beta), and tissue inhibitor of metalloproteinase-1
(TIMP-1) gene expression during the development
of OA. Osteoarthritis Cartilage 1997;7:182e90.
46. Martel-Pelletier J, Zafarullah M, Kodama S, Pelletier JP.
In vitro effects of interleukin 1 on the synthesis of met-
alloproteases, TIMP, plasminogen activators and
249Osteoarthritis and Cartilage Vol. 14, No. 3inhibitors in human articular cartilage. J Rheumatol
1991;18:S80e4.
47. Sadowski T, Steinmyer J. Modulation of the synthesis
and activation of matrix metalloproteinases in IL-1-
treated chondrocytes by antirheumatic drugs. Ann N
Y Acad Sci 1999;878:612e4.
48. Nedelec E, Abid A, Cipolletta C, Presle N, Terlain B,
Netter P, et al. Stimulation of cyclooxygenase-2-activ-
ity by nitric oxide-derived species in rat chondrocyte:
lack of contribution to loss of cartilage anabolism.
Biochem Pharmacol 2001;61:965e78.
49. Araghi-Niknam M, Liang B, Zhang Z, Ardestani SK,
Watson RR. Modulation of immune dysfunction during
murine leukemia retrovirus infection of old mice by de-
hydroepiandrosterone sulfate (DHEAS). Immunology
1997;90:344e9.
50. Ben-Nathan D, Padgett DA, Loria RM. Androstenediol
and dehydroepiandrosterone protect mice against le-
thal bacterial infections and lipopolysaccharide tox-
icity. J Med Microbiol 1999;48:425e31.
51. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M,
Scholmerich J, et al. Serum dehydroepiandrosterone
(DHEA) and DHEA sulfate are negatively correlated
with serum interleukin-6 (IL-6), and DHEA inhibits IL-6
secretion from mononuclear cells in man in vitro: possi-
ble link between endocrinosenescence and immunose-
nescence. J Clin Endocrinol Metab 1998;83:2012e7.
52. Poynter ME, Daynes RA. Peroxisome proliferator acti-
vated receptor alpha activation modulates cellularredox status, represses nuclear factor-kappaB signal-
ing, and reduces inﬂammatory cytokine production in
again. J Biol Chem 1998;273:32833e41.
53. Dashtaki R, Whorton AR, Murphy TM, Chitano P,
Reed W, Kennedy TP. Dehydroepiandrosterone and
analogs inhibit DNA binding of AP-1 and airway
smooth muscle proliferation. J Pharmacol Exp Ther
1998;285:876e83.
54. Schmidt M, Kreutz M, Lofﬂer G, Scholmerich J,
Straub RH. Conversion of dehydroepiandrosterone
to downstream steroid hormones in macrophages.
J Endocrinol 2000;164:161e9.
55. Geng Y, Valbracht J, Lotz M. Selective activation of the
mitogen-activated protein kinase subgroups c-Jun
NH2 terminal kinase and p38 by IL-1 and TNF in hu-
man articular chondrocytes. J Clin Invest 1996;98:
2425e30.
56. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor
kappaB/p50 activates an element in the distal matrix
metalloproteinase 1 promoter in interleukin-1beta stim-
ulated synovial ﬁbroblasts. Arthritis Rheum 1998;41:
1987e94.
57. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A,
Brinckerhoff CE. Interleukin-1 induction of collagenase
3 (matrix metalloproteinase 13) gene expression in
chondrocytes requires p38, c-Jun N-terminal kinase,
and nuclear factor [kappa]B: differential regulation of
collagenase 1 and collagenase 3. Arthritis Rheum
2000;43:801e11.
